UH Cancer Center, Hawaii Cancer Consortium join national COVID-19 study
University of Hawaiʻi at Mānoa
The University of Hawai‘i Cancer Center and its clinical partners in the Hawai‘i Cancer Consortium have joined a national study, The COVID-19 and Cancer Consortium, to better understand the impact of the coronavirus on cancer patients. Led by Vanderbilt University, the study will collect information about cancer patients who contract COVID-19, and are receiving treatment at The Queen's Medical Center, Hawai‘i Pacific Health Hospitals, Hawaii Cancer Care and Hawaii Oncology Inc.
“It’s critically important that we participate in a study like this so that we have information about how our population of cancer patients respond to the COVID-19 virus. Our participation will ensure that the findings will have direct relevance for the people of Hawai‘i,” said Jared Acoba, UH Cancer Center assistant professor and oncologist at Hawaii Oncology Inc., who will serve as the local principal investigator for the study.
“One of the key activities of the UH Cancer Center is to make available and to coordinate national cancer clinical research activities for all of our partners in our clinical trials network. We’re very pleased to be able to bring this study forward and appreciate the strong support for activating this study from hospital and physician leadership,” said Kate Bryant-Greenwood, manager of the UH Cancer Center’s Clinical Trials office.
The Hawaii Cancer Consortium includes the UH Cancer Center, John A. Burns School of Medicine, The Queen’s Health System, Hawai‘i Pacific Health, Kuakini Medical Center and Hawaii Medical Service Association. These entities, along with many oncology focused private practices including Hawaii Cancer Care, Hawaii Oncology Inc, The Cancer Center of Hawaii, Island Urology Oahu, Family Health Plan in Guam, and Tripler Army Medical Center, comprise the UH Cancer Center led cancer clinical trials network.
“Bringing the best care to cancer patients is our mission, and here in Hawai‘i we are fortunate to have all of these different entities working together to achieve this goal,” said Randall Holcombe, director of the UH Cancer Center.
The Vanderbilt University study on COVID-19 and cancer is now active. More information can be obtained by calling the Clinical Trials Office at UH Cancer Center at 808-586-2979.
About the University of Hawaiʻi Cancer Center
The University of Hawaiʻi Cancer Center through its various activities, including scientific research and clinical trials, adds more than $54 million to the Oʻahu economy. It is one of only 71 research institutions designated by the National Cancer Institute. Affiliated with the University of Hawaiʻi at Mānoa, the Center is dedicated to eliminating cancer through research, education, patient care and community outreach with an emphasis on the unique ethnic, cultural, and environmental characteristics of Hawaiʻi and the Pacific. Learn more at www.uhcancercenter.org. Like us on Facebook at www.facebook.com/UHCancerCenter. Follow us on Twitter @UHCancerCenter
For more information, visit: http://www.uhcancercenter.org